Search for a trial

A randomized, double-blind, vehicle-controlled trial with safety run-in to assess the safety, tolerability and efficacy of DLQ02, a novel topical formulation Cyclosporine A (CsA), applied twice daily over four weeks to patients with plaque psoriasis.

To assess the safety, tolerability, pharmacodynamics and efficacy of two DLQ02 topical formulations in patients with plaque psoriasis. To assess systemic exposure of CsA and F6H8 after topical application.